Search

Your search keyword '"Pison, C."' showing total 771 results
Start Over Author "Pison, C."
771 results on '"Pison, C."'

1. Extracorporeal Artificial Lungs: Co-Creating Future Technology – A Qualitative Analysis

Author

Dormann J, Wendt S, Dreher M, Ansems K, Rolland C, Spillner J, Szafran A, Breuer T, Pison C, Verbelen T, and Benstoem C

Subjects
chronic obstructive pulmonary disease, pulmonary hypertension, artificial lung, patient feedback, Medical technology, R855-855.5
Abstract

Julia Dormann,1 Sebastian Wendt,1 Michael Dreher,2 Kelly Ansems,1 Carole Rolland,3 Jan Spillner,4 Agnieszka Szafran,1 Thomas Breuer,1 Christophe Pison,5– 7,&ast; Tom Verbelen,8,&ast; Carina Benstoem1,&ast; 1Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Aachen, Germany; 2Department of Pneumology and Intensive Care Medicine, RWTH Aachen University, Aachen, Germany; 3Techniques de l’Ingénierie Médicale et de la Complexité (TIMC), Centre National de la Recherche Scientifique (CNRS), University Grenoble Alpes, Grenoble, France; 4Department of Thoracic Surgery, Medical Faculty, RWTH Aachen University, Aachen, Germany; 5Department of Pneumology and Physiology, CHU Grenoble Alpes; University Grenoble Alpes, Grenoble, France; 6Laboratory of Fundamental and Applied Bioenergetics, LBFA, Inserm1055, Grenoble, France; 7Département Universitaire des Patients Grenoble Alpes, University Grenoble Alpes, Grenoble, France; 8Department of Cardiovascular Sciences, KU Leuven and Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium&ast;These authors contributed equally to this workCorrespondence: Carina Benstoem, Department of Intensive Care Medicine and Intermediate Care, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, Aachen, D-52074, Tel +49 241 80 38038, Fax +49 241 80 33 82182, Email cbenstoem@ukaachen.deBackground: Terminal lung diseases such as chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH) in progression cause a large reduction in quality of life and may lead to bilateral lung transplantation (bLTx). An artificial portable lung could provide a bridge to lung transplantation, allowing patients to remain at home and mobile for longer. To advance the development of such an artificial lung, patient feedback is essential. The aim of this study is to analyze patient acceptance about an extracorporeal artificial lung and to implement these findings into the development.Methods: In collaboration with a medical device developer, we presented a portable dummy oxygenator to patients with advanced lung disease, as potential end users. Data collection in Germany and France was based on two different methods: an online questionnaire and face-to-face interviews (F2F).Results: A total of 604 participants answered the online questionnaire and 17 participants were included in the F2F interviews. The majority of participants (COPD n=140, PH n=17) were able to walk more than 1 km with a mean suffering pressure of 2.87 and 3, respectively. Six of the 17 F2F participants who could walk < 1 km were interested in an assistive device. The statistical value of Fisher’s exact test for suffering pressure and desire for a portable oxygenator was 0.45.Conclusion: In patients with advanced lung disease, there is no statistically significant association between subjectively increased suffering pressure and desire for a portable oxygenator, so market introduction may be difficult. Potential end users should be implemented early in device development. Data collection via an online questionnaire combined with personal interviews has proven to be a successful approach here.Keywords: chronic obstructive pulmonary disease, pulmonary hypertension, artificial lung, patient feedback

Published
2023

4. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Author

Badorrek, P., Broeders, M., Boersma, W.G., Chetta, A., Cukier, A., D'Amato, M., Djukanovic, R., Foschino, M.P., Gessner, C., Hanania, N., Martin, R., Milleri, S., Olivenstein, R., Paggiaro, P., Pizzichini, E., Plaza Moral, V., Postma, D.S., Scichilone, N., Schilz, R., Spanevello, A., Stelmach, R., Vroegop, J.S., Usmani, O.S., Zhang, Q., Ahmed, H., Allen, D., Ballereau, S., Batuwitage, M.K., Bedding, A., Behndig, A.F., Berglind, A., Berton, A., Bigler, J., Boedigheimer, M.J., Bønnelykke, K., Brinkman, P., Bush, A., Campagna, D., Casaulta, C., Chaiboonchoe, A., Davison, T., De Meulder, B., Delin, I., Dennison, P., Dodson, P., El Hadjam, L., Erzen, D., Faulenbach, C., Fichtner, K., Fitch, N., Formaggio, E., Gahlemann, M., Galffy, G., Garissi, D., Garret, T., Guillmant-Farry, E., Henriksson, E., Hoda, U., Hohlfeld, J.M., Hu, X., James, A., Johnson, K., Jullian, N., Kerry, G., Klüglich, M., Knowles, R., Konradsen, J.R., Kretsos, K., Krueger, L., Lantz, A-S., Larminie, C., Latzin, P., Lefaudeux, D., Lemonnier, N., Lowe, L.A., Lutter, R., Manta, A., Mazein, A., McEvoy, L., Menzies-Gow, A., Mores, N., Murray, C.S., Nething, K., Nihlén, U., Niven, R., Nordlund, B., Nsubuga, S., Pellet, J., Pison, C., Praticò, G., Puig Valls, M., Riemann, K., Rocha, J.P., Rossios, C., Santini, G., Sagi, M., Scott, S., Sehgal, N., Selby, A., Söderman, P., Sogbesan, A., Spycher, F., Stephan, S., Stokholm, J., Sunther, M., Szentkereszty, M., Tamasi, L., Tariq, K., Valente, S, Van Aalderen, W.M., Van Drunen, C.M., Van Eyll, J., Vyas, A., Yu, W., Zetterguist, W., Zolkipli, Z., Zwinderman, A.H., Agusti, A., Wedzicha, J.A., Donaldson, G.C., Faner, R., Breyer-Kohansal, R., Maitland-van der Zee, A.H., Melén, E., Allinson, J.P., Vanfleteren, L.E.G.W., Vestbo, J., Adcock, I.M., Lahousse, L., Van den Berge, M., Alter, P., Barbe, F., Brightling, C.E., Breyer, M.K., Burghuber, O.C., Casas, M., Chung, K.F., Cosío, B.G., Crispi, F., De Batlle, J., Fitting, J.W., Garcia, J., Hallberg, J., Hartl, S., Jarvis, D., Mathioudakis, A., Nicod, L., Papi, A., Ritchie, A., Sigsgaard, T., Sterk, P.J., Ullman, A., Vellvé, K., Vogelmeier, C., Wheelock, A.M., Wheelock, C.E., Kole, Tessa M, Vanden Berghe, Elise, Kraft, Monica, Vonk, Judith M, Nawijn, Martijn C, Siddiqui, Salman, Sun, Kai, Fabbri, Leonardo M, Rabe, Klaus F, Chung, Kian Fan, Nicolini, Gabriele, Papi, Alberto, Brightling, Chris, Singh, Dave, van der Molen, Thys, Dahlén, Sven-Erik, Agusti, Alvar, Faner, Rosa, Wedzicha, Jadwiga A, Donaldson, Gavin C, Adcock, Ian M, Lahousse, Lies, Kerstjens, Huib A M, and van den Berge, Maarten

Published
2023
Full Text
View/download PDF

5. Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022

Author

Le Pavec, J., Pison, C., Hirschi, S., Bunel, V., Mordant, P., Brugière, O., Le Guen, M., Olland, A., Coiffard, B., Renaud-Picard, B., Tissot, A., Brioude, G., Borie, R., Crestani, B., Deslée, G., Stelianides, S., Mal, H., Schuller, A., Falque, L., Lorillon, G., Tazi, A., Burgel, P.R., Grenet, D., De Miranda, S., Bergeron, A., Launay, D., Cottin, V., Nunes, H., Valeyre, D., Uzunhan, Y., Prévot, G., Sitbon, O., Montani, D., Savale, L., Humbert, M., Fadel, E., Mercier, O., Mornex, J.F., Dauriat, G., and Reynaud-Gaubert, M.

Published
2022
Full Text
View/download PDF

6. Atteinte pulmonaire du déficit en alpha-1 antitrypsine. Recommandations pratiques pour le diagnostic et la prise en charge

Author

Mornex, J.-F., Balduyck, M., Bouchecareilh, M., Cuvelier, A., Epaud, R., Kerjouan, M., Le Rouzic, O., Pison, C., Plantier, L., Pujazon, M.-C., Reynaud-Gaubert, M., Toutain, A., Trumbic, B., Willemin, M.-C., Zysman, M., Brun, O., Campana, M., Chabot, F., Chamouard, V., Dechomet, M., Fauve, J., Girerd, B., Gnakamene, C., Lefrançois, S., Lombard, J.-N., Maitre, B., Maynié-François, C., Moerman, A., Payancé, A., Reix, P., Revel, D., Revel, M.-P., Schuers, M., Terrioux, P., Theron, D., Willersinn, F., Cottin, V., and Mal, H.

Published
2022
Full Text
View/download PDF

8. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2

Author

Valipour A, Shah PL, Herth FJ, Pison C, Schumann C, Hübner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Conway F, Duller M, Mayse M, Norman HS, and Slebos DJ

Subjects
copd exacerbation, targeted lung denervation, bronchoscopy, copd, Diseases of the respiratory system, RC705-779
Abstract

Arschang Valipour,1 Pallav L Shah,2 Felix J Herth,3 Christophe Pison,4 Christian Schumann,5 Ralf-Harto Hübner,6 Peter I Bonta,7 Romain Kessler,8 Wolfgang Gesierich,9 Kaid Darwiche,10 Bernd Lamprecht,11 Thierry Perez,12 Dirk Skowasch,13 Gaetan Deslee,14 Armelle Marceau,15 Frank C Sciurba,16 Reinoud Gosens,17 Jorine E Hartman,18 Francesca Conway,2 Marina Duller,1 Martin Mayse,19 Holly S Norman,19 Dirk-Jan Slebos18 On behalf of the AIRFLOW-2 Trial Study Group1Department of Respiratory and Critical Care Medicine, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Krankenhaus Nord-Klinik Floridsdorf, Vienna, Austria; 2Royal Brompton & Harefield NHS Trust, Chelsea & Westminster Hospital and Imperial College, London, UK; 3Thoraxklinik, Department of Pneumology and Critical Care Medicine and Translational Lung Research Center Heidelberg (TLRCH), University of Heidelberg, Heidelberg, Germany; 4CHU Grenoble Alpes, Service Hospitalier Universitaire Pneumologie Physiologie; Université Grenoble Alpes, Grenoble, France; 5Clinic of Pneumology, Thoracic Oncology, Sleep- and Respiratory Critical Care, Klinikverbund Allgaeu, Kempten and Immenstadt, Germany; 6Charité Universitätsmedizin Berlin, Medizinische Klinik m. Schw. Infektiologie und Pneumologie, Campus Virchow, Berlin, Germany; 7Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 8Service de Pneumologie, Nouvel Hôpital Civil, Université de Strasbourg, Strasbourg, France; 9Asklepios-Fachkliniken Munich-Gauting, Comprehensive Pneumology Center Munich, Gauting, Germany; 10Department of Pulmonary Medicine, Section of Interventional Pneumology, Ruhrlandklinik - University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 11Department of Pulmonary Medicine, Kepler Universitatsklinikum GmbH, Linz, Austria; 12CHU de Lille – Hôpital Calmette, Lille, France; 13Department of Internal Medicine II - Cardiology/Pneumology, University of Bonn, Bonn, Germany; 14CHU de Reims, Hôpital Maison Blanche, Service de Pneumologie, Reims, France; 15Service de Pneumologie, Hôpital Universitaire Bichat, Paris, France; 16University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 17Department of Molecular Pharmacology, University of Groningen, Groningen, the Netherlands; 18Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 19Nuvaira, Inc., Minneapolis, MN, USACorrespondence: Dirk-Jan SlebosDepartment of Pulmonary Diseases/Interventional Bronchoscopy AA11, University Medical Center Groningen, PO Box 30001, Groningen, the NetherlandsTel +31 503612357Fax +31503619320Email d.j.slebos@umcg.nlPurpose: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to reduce clinical consequences of cholinergic hyperactivity and its impact on COPD exacerbations. The AIRFLOW-2 study assessed the durability of safety and efficacy of TLD additive to optimal drug therapy compared to sham bronchoscopy and optimal drug therapy alone in subjects with moderate-to-severe, symptomatic COPD two years post randomization.Patients and Methods: TLD was performed in COPD patients (FEV1 30– 60% predicted, CAT≥ 10 or mMRC≥ 2) in a 1:1 randomized, sham-controlled, double-blinded multicenter study (AIRFLOW-2) using a novel lung denervation system (Nuvaira, Inc., USA). Subjects remained blinded until their 12.5-month follow-up visit when control subjects were offered the opportunity to undergo TLD. A time-to-first-event analysis on moderate and severe and severe exacerbations of COPD was performed.Results: Eighty-two subjects (FEV1 41.6± 7.4% predicted, 50.0% male, age 63.7± 6.8 yrs, 24% with prior year respiratory hospitalization) were randomized. Time-to-first severe COPD exacerbation was significantly lengthened in the TLD arm (p=0.04, HR=0.38) at 2 years post-TLD therapy and trended towards similar attenuation for moderate and severe COPD exacerbations (p=0.18, HR=0.71). No significant changes in lung function or SGRQ-C were found 2 years post randomization between groups.Conclusion: In a randomized trial, TLD demonstrated a durable effect of significantly lower risk of severe AECOPD over 2 years. Further, lung function and quality of life remained stable following TLD.Clinical Trial Registration: NCT02058459.Keywords: COPD exacerbation, targeted lung denervation, bronchoscopy, COPD

Published
2020

9. IL-17–high asthma with features of a psoriasis immunophenotype

Author

Adcock, I.M., Ahmed, H., Auffray, C., Bakke, P., Bansal, A.T., Baribaud, F., Bates, S., Bel, E.H., Bigler, J., Bisgaard, H., Boedigheimer, M.J., Bønnelykke, K., Brandsma, J., Brinkman, P., Bucchioni, E., Burg, D., Bush, A., Caruso, M., Chaiboonchoe, A., Chanez, P., Chung, K.F., Compton, C.H., Corfield, J., D'Amico, A., Dahlen, S.E., De Meulder, B., Djukanovic, R., Erpenbeck, V.J., Erzen, D., Fichtner, K., Fitch, N., Fleming, L.J., Formaggio, E., Fowler, S.J., Frey, U., Gahlemann, M., Geiser, T., Guo, Y., Hashimoto, S., Haughney, J., Hedlin, G., Hekking, P.W., Higenbottam, T., Hohlfeld, J.M., Holweg, C., Horváth, I., Howarth, P., James, A.J., Knowles, R., Knox, A.J., Krug, N., Lefaudeux, D., Loza, M.J., Lutter, R., Manta, A., Masefield, S., Mazein, A., Meiser, A., Middelveld, R.J.M., Miralpeix, M., Montuschi, P., Mores, N., Murray, C.S., Musial, J., Myles, D., Pahus, L., Pandis, I., Pavlidis, S., Powell, P., Praticò, G., Rao, M. Puig N., Riley, J., Roberts, A., Roberts, G., Rowe, A., Sandström, T., Seibold, W., Selby, A., Shaw, D.E., Sigmund, R., Singer, F., Skipp, P.J., Sousa, A.R., Sterk, P.J., Sun, K., Thornton, B., van Aalderen, W.M., van Geest, M., Vestbo, J., Vissing, N.H., Wagener, A.H., Wagers, S.S., Weiszhart, Z., Wheelock, C.E., Wilson, S.J., Aliprantis, Antonios, Allen, David, Alving, Kjell, Badorrek, P., Balgoma, David, Ballereau, S., Barber, Clair, Batuwitage, Manohara Kanangana, Bautmans, A., Bedding, A., Behndig, A.F., Beleta, Jorge, Berglind, A., Berton, A., Bochenek, Grazyna, Braun, Armin, Campagna, D., Carayannopoulos, Leon, Casaulta, C., Chaleckis, Romanas, Dahlén, B., Davison, imothy, De Alba, Jorge, De Lepeleire, Inge, Dekker, Tamara, Delin, Ingrid, Dennison, P., Dijkhuis, Annemiek, Dodson, Paul, Draper, Aleksandra, Dyson, K., Edwards, Jessica, El Hadjam, L., Emma, Rosalia, Ericsson, Magnus, Faulenbach, C., Flood, Breda, Galffy, G., Gallart, Hector, Garissi, D., Gent, J., Gerhardsson de Verdier, M., Gibeon, D., Gomez, Cristina, Gove, Kerry, Gozzard, Neil, Guillmant-Farry, E., Henriksson, E., Hewitt, Lorraine, Hoda, U., Hu, Richard, Hu, Sile, Hu, X., Jeyasingham, E., Johnson, K., Jullian, N., Kamphuis, Juliette, Kennington, Erika J., Kerry, Dyson, Kerry, G., Klüglich, M., Knobel, Hugo, Kolmert, Johan, Konradsen, J.R., Kots, Maxim, Kretsos, Kosmas, Krueger, L., Kuo, Scott, Kupczyk, Maciej, Lambrecht, Bart, Lantz, A.-S., Larminie, Christopher, Larsson, L.X., Latzin, P., Lazarinis, N., Lemonnier, N., Lone-Latif, Saeeda, Lowe, L.A., Manta, Alexander, Marouzet, Lisa, Martin, Jane, Mathon, Caroline, McEvoy, L., Meah, Sally, Menzies-Gow, A., Metcalf, Leanne, Mikus, Maria, Monk, Philip, Naz, Shama, Nething, K., Nicholas, Ben, Nihlén, U., Nilsson, Peter, Niven, R., Nordlund, B., Nsubuga, S., Pacino, Antonio, Palkonen, Susanna, Pellet, J., Pennazza, Giorgio, Petrén, Anne, Pink, Sandy, Pison, C., Postle, Anthony, Rahman-Amin, Malayka, Ravanetti, Lara, Ray, Emma, Reinke, Stacey, Reynolds, Leanne, Riemann, K., Robberechts, Martine, Rocha, J.P., Rossios, C., Russell, Kirsty, Rutgers, Michael, Santini, G., Santoninco, Marco, Saqi, M., Schoelch, Corinna, Schofield, James P.R., Scott, S., Sehgal, N., Sjödin, Marcus, Smids, Barbara, Smith, Caroline, Smith, Jessica, Smith, Katherine M., Söderman, P., Sogbessan, A., Spycher, F., Staykova, Doroteya, Stephan, S., Stokholm, J., Strandberg, K., Sunther, M., Szentkereszty, M., Tamasi, L., Tariq, K., Thörngren, John-Olof, Thorsen, Jonathan, Valente, S., van de Pol, Marianne, van Drunen, C.M., Van Eyll, Jonathan, Versnel, Jenny, Vink, Anton, von Garnier, C., Vyas, A., Wald, Frans, Walker, Samantha, Ward, Jonathan, Wetzel, Kristiane, Wiegman, Coen, Williams, Siân, Yang, Xian, Yeyasingham, Elizabeth, Amgen, W. Yu, Zetterquist, W., Zolkipli, Z., Zwinderman, A.H., Östling, Jörgen, van Geest, Marleen, Jevnikar, Zala, Wilson, Susan, Lutter, Rene, Shaw, Dominick E., Bakke, Per S., Caruso, Massimo, Dahlen, Sven-Erik, Fowler, Stephen J., Horváth, Ildikó, Krug, Norbert, Montuschi, Paolo, Sanak, Marek, Sandström, Thomas, Sun, Kai, Pandis, Ioannis, Auffray, Charles, Sousa, Ana R., Guo, Yike, Adcock, Ian M., Howarth, Peter, Chung, Kian Fan, Bigler, Jeanette, Sterk, Peter J., Skipp, Paul J., Djukanović, Ratko, and Vaarala, Outi

Published
2019
Full Text
View/download PDF

10. Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism

Author

Klok, Frederikus A., Presles, Emilie, Tromeur, Cecile, Barco, Stefano, Konstantinides, Stavros V., Sanchez, Olivier, Pernod, Gilles, Raj, Leela, Robin, Philippe, Le Roux, Pierre‐Yves, Hoffman, Clément, Mélac, Solen, Bertoletti, Laurent, Girard, Philippe, Laporte, Silvy, Mismetti, Patrick, Meyer, Guy, Leroyer, Christophe, Couturaud, Francis, Jego, P., Duhamel, E., Provost, K., Parent, F., Mottier, D., Guégan, M., Le Hir, A., Lenoir, S., Lamer, C., Bergmann, J.F., Wahl, D., Drouet, L., Chevarier, P., Monte, N., Morvan, F., Kouassi, V., Ibrir, N., El Asri, G., Salaun, P.Y., Bressollette, L., Quéhé, P., Gestin, S., Nonent, M., Bahuon, J., Deloire, L., Planquette, B., Jobic, Y., Etienne, Y., Didier, R., Leven, F., Leroux, L., Galinat, H., Le Maréchal, C., Gourhant, L., Mingant, F., Lacut, K., Lemoigne, E., De Saint Martin, L., Delluc, A., Le Gal, G., Paleiron, N., Le Mao, R., Pison, C., Guéret, P., Décousus, H., Lassagne, C., Pan‐Petesh, B., Bura‐Riviere, A., Delahousse, B., Gruel, Y., Lorut, C., Schmidt, J., and Connault, J.

Published
2019
Full Text
View/download PDF

11. Spectrum of Pulmonary Aspergillosis in Hyper-IgE Syndrome with Autosomal-Dominant STAT3 Deficiency

Author

Coignard, H., Amazzough, K., Suarez, F., Blanche, S., Sendid, B., Cornu, M., Bervar, J.F., Deschildre, A., Wemeau, L., Fieschi, C., Alanio, A., Menetrey, C., Senechal, A., Ader, F., Tattevin, P., Pison, C., Grandiere-Perez, L., Garcia-Hermoso, D., Botterel-Chartier, F., Duréault, Amélie, Tcherakian, Colas, Poiree, Sylvain, Catherinot, Emilie, Danion, François, Jouvion, Grégory, Bougnoux, Marie Elisabeth, Mahlaoui, Nizar, Givel, Claire, Castelle, Martin, Picard, Capucine, Chansdesris, Marie Olivia, Lortholary, Olivier, and Lanternier, Fanny

Published
2019
Full Text
View/download PDF

12. Stratification of asthma phenotypes by airway proteomic signatures

Author

Ahmed, H., Allen, D., Badorrek, P., Ballereau, S., Baribaud, F., Bedding, A., Behndig, A.F., Berglind, A., Berton, A., Bigler, J., Boedigheimer, M.J., Bønnelykke, K., Brinkman, P., Bush, A., Campagna, D., Casaulta, C., Chaiboonchoe, A., Davison, T., De Meulder, B., Delin, I., Dennison, P., Dodson, P., El Hadjam, L., Erzen, D., Faulenbach, C., Fichtner, K., Fitch, N., Formaggio, E., Gahlemann, M., Galffy, G., Garissi, D., Garret, T., Gent, J., Guillmant-Farry, E., Henriksson, E., Hoda, U., Hohlfeld, J.M., Hu, X., James, A., Johnson, K., Jullian, N., Kerry, G., Klüglich, M., Knowles, R., Konradsen, J.R., Kretsos, K., Krueger, L., Lantz, A.-S., Larminie, C., Latzin, P., Lefaudeux, D., Lemonnier, N., Lowe, L.A., Lutter, R., Manta, A., Mazein, A., McEvoy, L., Menzies-Gow, A., Mores, N., Murray, C.S., Nething, K., Nihlén, U., Niven, R., Nordlund, B., Nsubuga, S., Pellet, J., Pison, C., Praticò, G., Valls, M. Puig, Riemann, K., Rocha, J.P., Rossios, C., Santini, G., Saqi, M., Scott, S., Sehgal, N., Selby, A., Söderman, P., Sogbesan, A., Spycher, F., Stephan, S., Stokholm, J., Sunther, M., Szentkereszty, M., Tamasi, L., Tariq, K., Valente, S., van Aalderen, W.M., van Drunen, C.M., Van Eyll, J., Vyas, A., Yu, W., Zetterquist, W., Zolkipli, Z., Zwinderman, A.H., Schofield, James P.R., Burg, Dominic, Nicholas, Ben, Strazzeri, Fabio, Brandsma, Joost, Staykova, Doroteya, Folisi, Caterina, Bansal, Aruna T., Xian, Yang, Guo, Yike, Rowe, Anthony, Corfield, Julie, Wilson, Susan, Ward, Jonathan, Lutter, Rene, Shaw, Dominick E., Bakke, Per S., Caruso, Massimo, Dahlen, Sven-Erik, Fowler, Stephen J., Horváth, Ildikó, Howarth, Peter, Krug, Norbert, Montuschi, Paolo, Sanak, Marek, Sandström, Thomas, Sun, Kai, Pandis, Ioannis, Riley, John, Auffray, Charles, De Meulder, Bertrand, Lefaudeux, Diane, Sousa, Ana R., Adcock, Ian M., Chung, Kian Fan, Sterk, Peter J., Skipp, Paul J., and Djukanović, Ratko

Published
2019
Full Text
View/download PDF

15. PB1086 Time in Therapeutic Range after an Event: Where We Started from and Where Are We Going?

Author

Fernández Pérez, M., primary, Salcedo, L., additional, Ezkurra, M., additional, Pradera, A., additional, Pereda, A., additional, Pison, C., additional, Vega, A., additional, Unamunzaga, A., additional, Cuevas, L., additional, Gutierrez, X., additional, Buendia, B., additional, Gabilondo, M., additional, Robles, D., additional, de Miguel, C., additional, Rodriguez, F., additional, and Guinea, J., additional

Published
2023
Full Text
View/download PDF

16. Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency

Author

Perotin JM, Leroy S, Marquette CH, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Barbe C, and Deslee G

Subjects
emphysema, COPD, coil treatment, lung volume reduction, endobronchial., Diseases of the respiratory system, RC705-779
Abstract

Jeanne Marie Perotin,1 Sylvie Leroy,2 Charles Hugo Marquette,2 Hervé Mal,3 Hervé Dutau,4 Arnaud Bourdin,5 Jean Michel Vergnon,6 Christophe Pison,7 Coralie Barbe,8 Gaëtan Deslee1 On behalf of the REVOLENS Study Group 1Service de Pneumologie, INSERM U1250, Hôpital Universitaire, Reims, France; 2Service de Pneumologie, CHU de Nice, FHU OncoAge, Université Côte d’Azur, Nice, France; 3Service de Pneumologie, Hôpital Universitaire Bichat, Paris, France; 4Service d’Oncologie Thoracique, Maladies de la Plèvre, Pneumologie Interventionnelle, Hôpital Universitaire, Marseille, France; 5Département de Pneumologie et Addictologie, PhyMedExp, INSERM U1046, CNRS UMR, Hôpital Universitaire, Montpellier, France; 6Service de Pneumologie, Hôpital Universitaire, Saint Etienne, France; 7Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, Inserm1055, Hôpital Universitaire Grenoble Alpes, Université Grenoble Alpes, Grenoble, France; 8Département de Méthodologie, Pôle Recherche-Innovations, Hôpital Universitaire, Reims, France Abstract: Endobronchial coil treatment (ECT) is a minimally invasive procedure developed for palliative care of patients with severe emphysema. ECT has demonstrated a decrease in hyperinflation, an improvement in quality of life, and an acceptable safety profile in randomized controlled trials (RCTs). Because alpha-1 antitrypsin deficiency (AATD) is a classical exclusion criterion in RCTs, there is no available data for ECT in AATD. In this post hoc analysis of the REVOLENS study (Réduction volumique endobronchique par spirales; ClinicalTrials.gov Identifier: NCT01822795), a multicenter 1:1 RCT which compared bilateral ECT with usual care in severe emphysema, we analyzed the efficacy and safety results at 1 year in six patients with AATD (five males, one female; mean age: 52±9 years) who underwent ECT. A significant decrease in hyperinflation (0.35 L decrease in residual volume [RV]) was observed in four out of six patients at 6 months and three out of six patients at 12 months, and an improvement in quality of life (improvement of 4 points in the St George’s Respiratory Questionnaire [SGRQ]) was observed in four out of six patients at both 6 and 12 months. Efficacy results at 6 and 12 months from the six AATD patients were compared with 84 non-AATD patients who underwent ECT, and no statistically significant differences were found for FEV1, RV, 6MWT score and SGRQ score. Respiratory-related serious adverse event was limited to pneumonia in one AATD patient at 1 year post-ECT. This post hoc study suggests that AATD patients may have similar efficacy and safety outcomes at 1 year as non-AATD patients. Because of the paucity of available data, appropriately powered studies are needed to determine the effects of ECT in AATD. Keywords: COPD, volume reduction, interventional, bronchoscopy

Published
2018

17. Long-term safety of bilateral targeted lung denervation in patients with COPD

Author

Valipour A, Asadi S, Pison C, Jondot M, Kessler R, Benneddif K, Deslee G, Verdier M, Slebos DJ, and Mayse M

Subjects
Chronic obstructive pulmonary disease, bronchoscopy, radiofrequency ablation, denervation, device, Diseases of the respiratory system, RC705-779
Abstract

Arschang Valipour,1 Sherwin Asadi,1 Christophe Pison,2 Marie Jondot,2 Romain Kessler,3 Khaled Benneddif,3 Gaetan Deslee,4 Margaux Verdier,4 Dirk-Jan Slebos,5 Martin Mayse6 1Department of Respiratory and Critical Care Medicine, Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Spital, Vienna, Austria; 2CHU Grenoble Alpes, Clinique Universitaire de Pneumologie, Université Grenoble Alpes, Grenoble, France; 3Service de Pneumologie, Nouvel Hôpital Civil, Université de Strasbourg, Strasbourg, France; 4CHU de Reims, Hôpital Maison Blanche, Service de Pneumologie, INSERM UMRS903, Reims, France; 5Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 6Nuvaira, Inc., Minneapolis, MN, USA Background: Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD which ablates parasympathetic pulmonary nerves running along the outside of the two main bronchi with the intent of inducing permanent bronchodilation. The goal of this study was to evaluate the feasibility and long-term safety of bilateral TLD during a single procedure. Patients and methods: This prospective, multicenter study evaluated 15 patients with moderate-to-severe COPD (forced expiratory volume in 1 s [FEV1] 30%–60%) who underwent bilateral TLD treatment following baseline assessment without bronchodilators. The primary safety end point was freedom from documented and sustained worsening of COPD directly attributable to TLD up to 1 year. Secondary end points included technical feasibility, change in pulmonary function tests, exercise capacity, and health-related quality of life. Follow-up continued up to 3 years for subjects who reconsented for longer-term follow-up. Results: A total of 15 patients (47% male, age 63.2±4.0 years) underwent TLD with a total procedure time of 89±16 min, and the total fluoroscopy time was 2.5±2.7 min. Primary safety end point of freedom from worsening of COPD was 100%. There were no procedural complications reported. Results of lung function analysis and exercise capacity demonstrated similar beneficial effects of TLD without bronchodilators, when compared with long-acting anticholinergic therapy at 30 days, 180 days, 365 days, 2 years, and 3 years post-TLD. Five of the 12 serious adverse events that were reported through 3 years of follow-up were respiratory related with no events being related to TLD therapy. Conclusion: TLD delivered to both lungs in a single procedure is feasible and safe with few respiratory-related adverse events through 3 years. Keywords: COPD, bronchoscopy, radiofrequency ablation, denervation, device

Published
2018

19. T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase-9 via a C-C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction

Author

Pain, M., Royer, P.-J., Loy, J., Girardeau, A., Tissot, A., Lacoste, P., Roux, A., Reynaud-Gaubert, M., Kessler, R., Mussot, S., Dromer, C., Brugière, O., Mornex, J.-F., Guillemain, R., Dahan, M., Knoop, C., Botturi, K., Pison, C., Danger, R., Brouard, S., and Magnan, A.

Published
2017
Full Text
View/download PDF

24. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study

Author

Kole, Tessa M, primary, Vanden Berghe, Elise, additional, Kraft, Monica, additional, Vonk, Judith M, additional, Nawijn, Martijn C, additional, Siddiqui, Salman, additional, Sun, Kai, additional, Fabbri, Leonardo M, additional, Rabe, Klaus F, additional, Chung, Kian Fan, additional, Nicolini, Gabriele, additional, Papi, Alberto, additional, Brightling, Chris, additional, Singh, Dave, additional, van der Molen, Thys, additional, Dahlén, Sven-Erik, additional, Agusti, Alvar, additional, Faner, Rosa, additional, Wedzicha, Jadwiga A, additional, Donaldson, Gavin C, additional, Adcock, Ian M, additional, Lahousse, Lies, additional, Kerstjens, Huib A M, additional, van den Berge, Maarten, additional, Badorrek, P., additional, Broeders, M., additional, Boersma, W.G., additional, Chetta, A., additional, Cukier, A., additional, D'Amato, M., additional, Djukanovic, R., additional, Foschino, M.P., additional, Gessner, C., additional, Hanania, N., additional, Martin, R., additional, Milleri, S., additional, Olivenstein, R., additional, Paggiaro, P., additional, Pizzichini, E., additional, Plaza Moral, V., additional, Postma, D.S., additional, Scichilone, N., additional, Schilz, R., additional, Spanevello, A., additional, Stelmach, R., additional, Vroegop, J.S., additional, Usmani, O.S., additional, Zhang, Q., additional, Ahmed, H., additional, Allen, D., additional, Ballereau, S., additional, Batuwitage, M.K., additional, Bedding, A., additional, Behndig, A.F., additional, Berglind, A., additional, Berton, A., additional, Bigler, J., additional, Boedigheimer, M.J., additional, Bønnelykke, K., additional, Brinkman, P., additional, Bush, A., additional, Campagna, D., additional, Casaulta, C., additional, Chaiboonchoe, A., additional, Davison, T., additional, De Meulder, B., additional, Delin, I., additional, Dennison, P., additional, Dodson, P., additional, El Hadjam, L., additional, Erzen, D., additional, Faulenbach, C., additional, Fichtner, K., additional, Fitch, N., additional, Formaggio, E., additional, Gahlemann, M., additional, Galffy, G., additional, Garissi, D., additional, Garret, T., additional, Guillmant-Farry, E., additional, Henriksson, E., additional, Hoda, U., additional, Hohlfeld, J.M., additional, Hu, X., additional, James, A., additional, Johnson, K., additional, Jullian, N., additional, Kerry, G., additional, Klüglich, M., additional, Knowles, R., additional, Konradsen, J.R., additional, Kretsos, K., additional, Krueger, L., additional, Lantz, A-S., additional, Larminie, C., additional, Latzin, P., additional, Lefaudeux, D., additional, Lemonnier, N., additional, Lowe, L.A., additional, Lutter, R., additional, Manta, A., additional, Mazein, A., additional, McEvoy, L., additional, Menzies-Gow, A., additional, Mores, N., additional, Murray, C.S., additional, Nething, K., additional, Nihlén, U., additional, Niven, R., additional, Nordlund, B., additional, Nsubuga, S., additional, Pellet, J., additional, Pison, C., additional, Praticò, G., additional, Puig Valls, M., additional, Riemann, K., additional, Rocha, J.P., additional, Rossios, C., additional, Santini, G., additional, Sagi, M., additional, Scott, S., additional, Sehgal, N., additional, Selby, A., additional, Söderman, P., additional, Sogbesan, A., additional, Spycher, F., additional, Stephan, S., additional, Stokholm, J., additional, Sunther, M., additional, Szentkereszty, M., additional, Tamasi, L., additional, Tariq, K., additional, Valente, S, additional, Van Aalderen, W.M., additional, Van Drunen, C.M., additional, Van Eyll, J., additional, Vyas, A., additional, Yu, W., additional, Zetterguist, W., additional, Zolkipli, Z., additional, Zwinderman, A.H., additional, Agusti, A., additional, Wedzicha, J.A., additional, Donaldson, G.C., additional, Faner, R., additional, Breyer-Kohansal, R., additional, Maitland-van der Zee, A.H., additional, Melén, E., additional, Allinson, J.P., additional, Vanfleteren, L.E.G.W., additional, Vestbo, J., additional, Adcock, I.M., additional, Lahousse, L., additional, Van den Berge, M., additional, Alter, P., additional, Barbe, F., additional, Brightling, C.E., additional, Breyer, M.K., additional, Burghuber, O.C., additional, Casas, M., additional, Chung, K.F., additional, Cosío, B.G., additional, Crispi, F., additional, De Batlle, J., additional, Fitting, J.W., additional, Garcia, J., additional, Hallberg, J., additional, Hartl, S., additional, Jarvis, D., additional, Mathioudakis, A., additional, Nicod, L., additional, Papi, A., additional, Ritchie, A., additional, Sigsgaard, T., additional, Sterk, P.J., additional, Ullman, A., additional, Vellvé, K., additional, Vogelmeier, C., additional, Wheelock, A.M., additional, and Wheelock, C.E., additional

Published
2023
Full Text
View/download PDF

31. Évaluation multicentrique et randomisée de l’impact des conseillers en environnement intérieur sur le contrôle de l’asthme : l’étude ECENVIR

Author

Gangneux, J.P., primary, Morel, H., additional, Blanc, F.X., additional, Bonniaud, P., additional, Boza, G., additional, Briault, A., additional, Brouard, J., additional, Charpin, D., additional, Chenivesse, C., additional, Colas, H., additional, Cottereau, A., additional, Dalampira, G., additional, De Blay, F., additional, Debeillex, X., additional, Dumont, P., additional, Elchehaded, K., additional, Fayon, M., additional, Fry, S., additional, Hullo, E., additional, Leblanc, A., additional, Letreut, J., additional, Magnan, A., additional, Mahay, G., additional, Perotin-Collard, J.M., additional, Pegliasco, H., additional, Pin, I., additional, Pison, C., additional, Rossignoli, N., additional, Siao Him Fa, V., additional, Ziani Bey, H., additional, Com-Ruelle, L., additional, Morcet, J., additional, Oger, E., additional, and Le Cann, P., additional

Published
2022
Full Text
View/download PDF

32. Sarcoidosis, inorganic dust exposure and content of bronchoalveolar lavage fluid: the MINASARC pilot study

Author

Catinon, M., Cavalin, C., Chemarin, C., Rio, S., Roux, E., Pecquet, M., Blanchet, A. -S, Vuillermoz, S., Pison, C., Arbib, F., Bonneterre, V., dominique Valeyre, Freynet, O., Mornex, J. -F, Pacheco, Y., Freymond, N., Thivolet, F., Kambouchner, M., Bernaudin, J. -F, Nathalizio, A., Pradat, P., Rosental, P. -A, and Vincent, M.

Subjects
Original Article: Clinical Research, bronchoalveolar lavage, sarcoidosis, dust exposure, respiratory tract diseases
Abstract

Inhalation of mineral dust was suggested to contribute to sarcoidosis. We compared the mineral exposome of 20 sarcoidosis and 20 matched healthy subjects. Bronchoalveolar lavage (BAL) samples were treated by digestion-filtration and analyzed by transmission electron microscopy. The chemical composition of inorganic particles was determined by energy-dispersive X-ray (EDX) spectroscopy. Dust exposure was also assessed by a specific questionnaire. Eight sarcoidosis patients and five healthy volunteers had a high dust load in their BAL. No significant difference was observed between the overall inorganic particle load of each group while a significant higher load for steel was observed in sarcoidosis patients (p=0.029). Moreover, the building activity sub-score was significantly higher in sarcoidosis patients (p=0.018). These results suggest that building work could be a risk factor for sarcoidosis which could be considered at least in some cases as a granulomatosis caused by airborne inorganic dust. The questionnaire should be validated in larger studies. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 327-332)

Published
2020

33. French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency

Author

Mornex, J.-F., Balduyck, M., Bouchecareilh, M., Cuvelier, A., Epaud, R., Kerjouan, M., Le Rouzic, O., Pison, C., Plantier, L., Pujazon, M.-C., Reynaud-Gaubert, M., Toutain, A., Trumbic, B., Willemin, M.-C., Zysman, M., Brun, O., Campana, M., Chabot, F., Chamouard, V., Dechomet, M., Fauve, J., Girerd, B., Gnakamene, C., Lefrançois, S., Lombard, J.-N., Maitre, B., Maynié-François, C., Moerman, A., Payancé, A., Reix, P., Revel, D., Revel, M.-P., Schuers, M., Terrioux, P., Theron, D., Willersinn, F., Cottin, V., Mal, H., Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Maladies RAres du DEveloppement embryonnaire et du MEtabolisme : du Phénotype au Génotype et à la Fonction - ULR 7364 (RADEME), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, Université de Lille, Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche sur le Handicap Ventilatoire et Neurologique (GRHVN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre Hospitalier Intercommunal de Créteil (CHIC), Hôpital Pontchaillou, Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Grenoble Alpes (UGA), Service de pneumologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Nord [CHU - APHM], Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Aix Marseille Université (AMU), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Service de génétique [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de pneumologie et d'allergologie respiratoire [Perpignan], Centre Hospitalier Régional d'Orléans (CHRO), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de Référence de l’Hypertension Pulmonaire Sévère [CHU Le Kremlin Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Faculté de Médecine Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Centre Hospitalier Montélimar, CH Montélimar, Physiopathologie des Maladies du Système Nerveux Central, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon, Hôpital Jeanne de Flandre [Lille], Centre de référence des Maladies Vasculaires du Foie [Paris] (FILFOIE), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d’Hépatologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and AP-HP - Hôpital Bichat - Claude Bernard [Paris]

Subjects
Déficit en alpha 1-antitrypsine, Cirrhose du foie, Emphysème pulmonaire, Bronchopneumopathie chronique obstructive, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Abstract

International audience; Contexte: Le déficit en alpha 1-antitrypsine (DAAT) est une maladie génétique autosomique récessive associée à l’état homozygote du variant Z du gène SERPINA1. Les manifestations cliniques sont un déficit sévère en alpha 1-antitrypsine, un emphysème pulmonaire et une fibrose hépatique.Méthodes: Des recommandations de prise en charge du DAAT ont été élaborées à l’initiative du centre coordonnateur de référence des maladies pulmonaires rares, sous l’égide de la Société de pneumologie de langue française, par des groupes de coordination, rédaction, et lecture, impliquant des pneumologues de divers modes d’exercice, biologistes, hépatologue, pharmacien hospitalier, conseiller en génétique, radiologues, médecins généralistes, cadre de santé, et associations de patients. La méthode d’élaboration des « Recommandations pour la pratique clinique » de la Haute autorité de santé a été suivie, incluant un vote en ligne selonune échelle Likert.Résultats: Après une analyse bibliographique, 20 recommandations ont été proposées par les groupes de travail, portant sur tous les aspects de la maladie : diagnostic biologique, bilan initial, conseils d’hygiène de vie, information, indications et modalités du traitement substitutif, dépistage.Conclusion: Ces recommandations fondées sur les preuves sont destinées à guider le diagnostic et la prise en charge pratique du DAAT.

Published
2022

34. Caractéristiques des patients inclus dans la cohorte d’asthme sévère RAMSES

Author

Devouassoux, G., primary, Chenivesse, C., additional, Bourdin, A., additional, Garcia, G., additional, Pison, C., additional, Boudjemaa, A., additional, Bonniaud, P., additional, Chanez, P., additional, Roux, P., additional, Beurnier, A., additional, Maurer, C., additional, Perotin-Collard, J.M., additional, Freymond, N., additional, Didi, T., additional, Tcherakian, C., additional, Russier, M., additional, Popin-Meyer, E., additional, Gauquelin, L., additional, Guillo, S., additional, Estellat, C., additional, and Taillé, C., additional

Published
2022
Full Text
View/download PDF

35. Profil clinique et qualité de vie des patients asthmatiques sévères de phénotype T2 traités par biothérapies en France : résultats en vraie vie de l’étude multicentrique « Second Souffle »

Author

Didier, A., primary, Raherison-Semjen, C., additional, Camus, C., additional, Verdier, E., additional, Bourdin, A., additional, Bonniaud, P., additional, Fry, S., additional, Devouassoux, G., additional, Blanc, F.X., additional, Pison, C., additional, Dupin, C., additional, Khayath, N., additional, Courdeau, J., additional, Valcke-Brossollet, J., additional, Nocent-Ejnaini, C., additional, Rolland, F., additional, Iamandi, C., additional, Proust, A., additional, Ozier, A., additional, Portel, L., additional, Gaspard, W., additional, Roux-Claude, P., additional, Beurnier, A., additional, Martinez, S., additional, Dot, J.M., additional, Hennegrave, F., additional, Vignal, G., additional, Auvray, E., additional, Paleiron, N., additional, Just, N., additional, Miltgen, J., additional, Russier, M., additional, Olivier, C., additional, Guilleminault, L., additional, and Taillé, C., additional

Published
2022
Full Text
View/download PDF

46. BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT)

Author

Jais, X., primary, Brenot, P., additional, Bouvaist, H., additional, Canuet, M., additional, Chabanne, C., additional, Chaouat, A., additional, Cottin, V., additional, Degroote, P., additional, Favrolt, N., additional, Horeau-Langlard, D., additional, Jevnikar, M., additional, Magro, P., additional, Montani, D., additional, Parent, F., additional, Pison, C., additional, Prévot, G., additional, Renard, S., additional, Savale, L., additional, Sitbon, O., additional, Trésorier, R., additional, Tromeur, C., additional, Piedvache, C., additional, Fadel, E., additional, Humbert, M., additional, and Simonneau, G., additional

Published
2021
Full Text
View/download PDF

47. Long-Term Follow-up of Severe Emphysema Patients Treated with Zephyr Valves in the Multicenter, Randomized TRANSFORM Study

Author

Slebos, D.-J., primary, Kornaszewska, M., additional, Kemp, S., additional, Kirk, A., additional, Carron, K., additional, mal, H., additional, Pison, C., additional, Downer, N., additional, Darwiche, K., additional, Rao, J., additional, Hubner, R.-H., additional, Trosini-Desert, V., additional, Eberhardt, R., additional, Derom, E., additional, Marquette, C.-H., additional, Shargill, N.S., additional, and Shah, P.L., additional

Published
2021
Full Text
View/download PDF

48. Infinitix-BOS Trial: Multi-Center, Randomised, Double-Blind Placebo-Controlled Trial of Nintedanib in Lung Transplant Recipients with Bronchiolitis Obliterans Syndrome (BOS) Grade 0-p and Grade 1-2

Author

Brugiere, O., primary, Picard, C., additional, Messika, J., additional, Weisenburger, G., additional, Bunel, V., additional, Demant, X., additional, Bon, c., additional, Macey, C., additional, Le Pavec, J., additional, Dauriat, G., additional, Crutu, A., additional, Hirschi, S., additional, Renaud Picard, b., additional, Degot, T., additional, Reynaud-Gaubert, M., additional, Coiffard, B., additional, Coltey, B., additional, Pison, C., additional, Raymond, C. Saint, additional, Briault, a., additional, Hamid, A., additional, Beaumont, L., additional, and Roux, A., additional

Published
2021
Full Text
View/download PDF

49. COVID-19 and beyond : a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight

Author

Auffray, C., Balling, R., Blomberg, N., Bonaldo, M. C., Boutron, B., Brahmachari, S., Bréchot, C., Cesario, A., Chen, S. -J, Clément, K., Danilenko, D., Meglio, A. D., Gelemanović, A., Goble, C., Gojobori, T., Goldman, J. D., Goldman, M., Guo, Y. -K, Heath, J., Hood, L., Hunter, P., Jin, L., Kitano, H., Knoppers, B., Lancet, D., Larue, C., Lathrop, M., Laville, M., Lindner, A. B., Magnan, A., Metspalu, A., Morin, E., Ng, L. F. P., Nicod, L., Noble, D., Nottale, L., Nowotny, H., Ochoa, T., Okeke, I. N., Oni, T., Openshaw, P., Oztürk, M., Palkonen, S., Paweska, J. T., Pison, C., Polymeropoulos, M. H., Pristipino, C., Protzer, U., Roca, J., Rozman, D., Santolini, M., Sanz, F., Scambia, G., Segal, E., Serageldin, I., Soares, M. B., Sterk, P., Sugano, S., Superti-Furga, G., Supple, D., Tegner, J., Uhlén, Mathias, Urbani, A., Valencia, A., Valentini, V., van der Werf, S., Vinciguerra, M., Wolkenhauer, O., Wouters, E., Auffray, C., Balling, R., Blomberg, N., Bonaldo, M. C., Boutron, B., Brahmachari, S., Bréchot, C., Cesario, A., Chen, S. -J, Clément, K., Danilenko, D., Meglio, A. D., Gelemanović, A., Goble, C., Gojobori, T., Goldman, J. D., Goldman, M., Guo, Y. -K, Heath, J., Hood, L., Hunter, P., Jin, L., Kitano, H., Knoppers, B., Lancet, D., Larue, C., Lathrop, M., Laville, M., Lindner, A. B., Magnan, A., Metspalu, A., Morin, E., Ng, L. F. P., Nicod, L., Noble, D., Nottale, L., Nowotny, H., Ochoa, T., Okeke, I. N., Oni, T., Openshaw, P., Oztürk, M., Palkonen, S., Paweska, J. T., Pison, C., Polymeropoulos, M. H., Pristipino, C., Protzer, U., Roca, J., Rozman, D., Santolini, M., Sanz, F., Scambia, G., Segal, E., Serageldin, I., Soares, M. B., Sterk, P., Sugano, S., Superti-Furga, G., Supple, D., Tegner, J., Uhlén, Mathias, Urbani, A., Valencia, A., Valentini, V., van der Werf, S., Vinciguerra, M., Wolkenhauer, O., and Wouters, E.

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) belongs to a subgroup of coronaviruses rampant in bats for centuries. It caused the coronavirus disease 2019 (COVID-19) pandemic. Most patients recover, but a minority of severe cases experience acute respiratory distress or an inflammatory storm devastating many organs that can lead to patient death. The spread of SARS-CoV-2 was facilitated by the increasing intensity of air travel, urban congestion and human contact during the past decades. Until therapies and vaccines are available, tests for virus exposure, confinement and distancing measures have helped curb the pandemic. Vision: The COVID-19 pandemic calls for safeguards and remediation measures through a systemic response. Self-organizing initiatives by scientists and citizens are developing an advanced collective intelligence response to the coronavirus crisis. Their integration forms Olympiads of Solidarity and Health. Their ability to optimize our response to COVID-19 could serve as a model to trigger a global metamorphosis of our societies with far-reaching consequences for attacking fundamental challenges facing humanity in the 21st century. Mission: For COVID-19 and these other challenges, there is no alternative but action. Meeting in Paris in 2003, we set out to "rethink research to understand life and improve health." We have formed an international coalition of academia and industry ecosystems taking a systems medicine approach to understanding COVID-19 by thoroughly characterizing viruses, patients and populations during the pandemic, using openly shared tools. All results will be publicly available with no initial claims for intellectual property rights. This World Alliance for Health and Wellbeing will catalyze the creation of medical and health products such as diagnostic tests, drugs and vaccines that become common goods accessible to all, while seeking further alliances with civil society to bridge with socio-ecological an, QC 20220519

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results